Displaying 146 (all) recruiting clinical trials.
-
STAMP: Surgically Treated Adjuvant Merkel cell Carcinoma with Pembrolizumab a Phase III Trial (ECOG EA6174)
This phase III trial studies how well pembrolizumab works compared to standard of care observation in treating patients with stage I-III Merkel cell cancer that ...Phase
Interventional
-
A Phase 1b Study of Nivolumab in Patients with Autoimmune Disorders and Advanced Malignancies (AIM-NIVO)
We want to know the safety and tolerability of the anti-programmed death 1 (PD-1) antibody nivolumab at different dose levels for patients with autoimmune disorders ...Phase
Interventional
-
A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants with Melanoma (KEYNOTE-U02): Substudy 02A
The purpose of the study is to determine the safety and tolerability of investigational treatment combinations with or without pembrolizumab or pembrolizumab alone for the ...Phase
Interventional
-
A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of lnvestigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants with Melanoma (KEYNOTE-U02): Substudy 02B Ph 1/2 Substudy of 1L Oncological Treatment(s) in Advanced MEL
The purpose of the study is to assess the efficacy of investigational treatment arms (pembrolizumab monotherapy or a unique pembrolizumab-based/ non-pembrolizumab-based combination) in participants with ...Phase
Interventional
-
ACNS1831: A Phase 3 Randomized Study of Selumetinib (IND # 77782) versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG)
The purpose of the study is to compare the efficacy of two treatments. The purpose is to determine whether the efficacy of treatment with selumetinib ...Phase
Interventional
-
Expanded Access to ONC201 for Patients with H3 K27M-mutant and/or Midline Gliomas
The purpose of this research study is to provide ONC201 to patients with specific forms of brain cancer who cannot access ONC201 by participating in ...Phase N/A Interventional
-
AALL1732 A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494 NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL Mixed Phenotype Acute Leukemia and Disseminated B-LLy
The purpose of the study is to determine the safety and efficacy of the investigational medicine Inotuzumab Ozogamicin for patients who have NCI high risk ...Phase
Interventional
-
AHEP1531: Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
This trial is the first international cooperative liver tumors trial in which a consensus approach was established by investigators representing Children’s Oncology Group (COG ...Phase
Interventional
-
AALL1732: A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494 NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL Mixed Phenotype Acute Leukemia and Disseminated B-LLy
The primary aim of this study is to assess in a randomized fashion whether or not the incorporation of two cycles of inotuzumab ozogamicin (InO ...Phase
Interventional
-
An Open-label Single-arm Single-dose Prospective Multicenter Phase 3 Study to Establish the Diagnostic Performance of 18F-Fluciclovine Positron Emission Tomography (PET) in Detecting Recurrent Brain Metastases after Radiation Therapy
The purpose of the study is to determine the diagnostic performance of 18F-Fluciclovine Positron Emission Tomography (PET) in detecting recurrent brain metastases after radiation therapy ...Phase
Interventional
